The American Psychiatric Publishing Textbook of Psychopharmacology, 4ed 2009

The American Psychiatric Association Publishing Textbook of Psychopharmacology is an indispensable and comprehensive resource for clinicians and trainees who prescribe psychotropic medications. Updated to reflect the new DSM-5 classification,  maintains the user-friendly structure of its predecessors while offering in-depth coverage of the latest research in pharmacological principles, classes of drugs, and psychiatric disorders. Introductory chapters provide a theoretical grounding in clinical applications, with topics ranging from neurotransmitters to brain imaging in psychopharmacology. The bulk of the book is devoted to various classes of drugs, including antidepressants, anxiolytics, antipsychotics, mood stabilizers, and other agents, with each class divided into chapters on specific drugs—either new or revised to include the latest findings and trends. Finally, the section on psychopharmacological treatment addresses evidence-based principles of clinical care for the full spectrum of mental disorders and conditions—from depression to chronic pain—as well as for specific populations and circumstances—from children and adolescents to psychiatric emergencies—offering information on topics such as medication selection, combination and maintenance dosing regimens, monitoring and management of side effects, and strategies for optimizing treatment response.

The book's beneficial features are many:

• The section on principles of pharmacology has been revised and reorganized to incorporate recent discoveries from the fields of neurobiology, genetics, brain imaging, and epidemiology.
• History and discovery, structure–activity relationships, pharmacological profiles, pharmacokinetics and disposition, mechanisms of action, indications and efficacy, side effects and toxicology, and drug–drug interactions are addressed for each agent. This consistent structure places the desired information at the clinician's fingertips and facilitates study for trainees.
• Coverage of drugs approved since the last edition is thorough, encompassing new antidepressants (e.g., vortioxetine), new antipsychotics (e.g., cariprazine), and agents on the clinical horizon (e.g., ketamine).
• More than 180 tables and graphs present critically important data in an accessible way.

A work of uncommon scientific rigor and clinical utility, The American Psychiatric Association Publishing Textbook of Psychopharmacology provides state-of-the-art information on both the principles and the practice of psychopharmacological treatment of psychiatric disorders.

• Contributors
• Introduction

• Part I: Principles of Pharmacology

• Chapter 1. Basic Principles of Molecular Biology and Genomics
• Chapter 2. Neurotransmitters
• Chapter 3. Genetics
• Chapter 4. Psychoneuroendocrinology
• Chapter 5. Brain–Immune System Interactions
• Chapter 6. Pharmacokinetics
• Chapter 7. Brain Imaging in Psychopharmacology

• Part II: Classes of Psychiatric Treatments Antidepressants and Anxiolytics

• Chapter 8. Monoamine Oxidase Inhibitors
• Chapter 9. Tricyclics
• Chapter 10. Fluoxetine
• Chapter 11. Sertraline
• Chapter 12. Paroxetine
• Chapter 13. Fluvoxamine
• Chapter 14. Citalopram
• Chapter 15. Trazodone and Nefazodone
• Chapter 16. Vortioxetine
• Chapter 17. Mirtazapine
• Chapter 18. Bupropion
• Chapter 19. Venlafaxine
• Chapter 20. Duloxetine, Milnacipran, and Levomilnacipran
• Chapter 21. Ketamine
• Chapter 22. Benzodiazepines
• Chapter 23. Buspirone

• Antipsychotics

• Chapter 24. Classic Antipsychotics
• Chapter 25. Clozapine
• Chapter 26. Olanzapine
• Chapter 27. Quetiapine
• Chapter 28. Risperidone and Paliperidone
• Chapter 29. Aripiprazole
• Chapter 30. Ziprasidone
• Chapter 31. Asenapine
• Chapter 32. Iloperidone
• Chapter 33. Lurasidone
• Chapter 34. Cariprazine
• Chapter 35. Drugs to Treat Extrapyramidal Side Effects
• Drugs for Treatment of Bipolar Disorder
• Chapter 36. Lithium
• Chapter 37. Valproate Bowden
• Chapter 38. Carbamazepine
• Chapter 39. Gabapentin
• Chapter 40. Lamotrigine
• Chapter 41. Topiramate

• Other Agents

• Chapter 42. Agents for Cognitive Disorders
• Chapter 43. Sedative-Hypnotics
• Chapter 44. Psychostimulants and Wakefulness-Promoting Agents
• Chapter 45. Neurostimulation

• Part III: Psychopharmacological Treatment

• Chapter 46. Treatment of Depression
• Chapter 47. Treatment of Bipolar Disorder
• Chapter 48. Treatment of Anxiety and Related Disorders
• Chapter 49. Treatment of Schizophrenia
• Chapter 50. Treatment of Substance-Related Disorders
• Chapter 51. Treatment of Personality Disorders
• Chapter 52. Treatment of Eating Disorders
• Chapter 53. Treatment of Insomnia
• Chapter 54. Treatment of Chronic Pain
• Chapter 55. Treatment of Child and Adolescent Disorders
• Chapter 56. Treatment During Late Life
• Chapter 57. Psychopharmacology During Pregnancy and Lactation
• Chapter 58. Treatment of Psychiatric Emergencies
• Chapter 59. Treatment of Agitation and Aggression in the Elderly

Alan F. Schatzberg, M.D., is Kenneth T. Norris Jr. Professor of the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine in Stanford, California. He is also the Director of the Mood Disorders Center at Stanford University.

Charles B. Nemeroff, M.D., Ph.D., is Leonard M. Miller Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine in Miami, Florida.